BioLineRx starts fourth cohort in Phase 1/2a trial of GLIX1 for high-grade glioma
BLRX•
BLRX•BioLineRx began dosing the fourth cohort in its Phase 1/2a high-grade glioma trial of GLIX1, with no significant treatment-emergent adverse events observed; clinical results are expected in the first half of 2027.
BioLineRx and Hemispherian presented clinical trial updates and preclinical findings at the 2026 Society for Neuro-Oncology annual meeting. The fourth cohort of the Phase 1/2a high-grade glioma trial has begun dosing, and no significant treatment-emergent adverse events have been observed.
Preclinical studies showed brain penetration and antitumor activity across glioblastoma models, including disease resistant to temozolomide. Remaining trial cohorts will include patients whose tumor tissue can be assessed directly for brain penetration and biological activity. Clinical results are expected in the first half of 2027.